布地奈德福莫特罗吸入剂联合氨溴索治疗COPD急性加重期的临床疗效  

The Clinical Effectiveness of Budesonide and Formoterol Powder for Inhalation Combined with Ambroxol of COPD Exacerbations in the Emergency

作　　者：张冈毅 莫鉴锋[1] 李绍清[1] 邓素贞 陈建初 张国明 颜育文 ZHANG Gang-yi;MO Jian-feng;LI Shao-qing;DENG Su-zhen;CHENJian-chu;ZHANG Guo-ming;YAN Yu-wen(The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan,Guangdong,511500)

机构地区：[1]广州医科大学附属第六医院,清远市人民医院,511500

出　　处：《岭南急诊医学杂志》2023年第2期124-125,133,共3页Lingnan Journal of Emergency Medicine

摘　　要：目的:分析布地奈德福莫特罗粉吸入剂联合氨溴索治疗COPD急性加重期的临床效果。方法:回顾分析我院2019年3月至2020年2月期间收治的COPD急性加重期患者80例,按治疗方式分组,其中40例接受布地奈德福莫特罗分吸入剂治疗(对照组),另40例接受布地奈德福莫特罗粉吸入剂联合氨溴索治疗(观察组),比较治疗效果,如疗效、肺功能、免疫功能指标等。结果:观察组治疗疗效显著高于对照组(95%vs 72.50%,P<0.05);比较肺功能指标,治疗前组间数据差异无统计学意义(P>0.05),治疗后,观察组PEF、FEV1、FVC明显高于对照组,差异有统计学意义(P<0.05);比较免疫功能指标,治疗前数据差异无统计学意义(P>0.05),治疗后,观察组CD4+/CD8+、CD4+、CD3+明显高于对照组,差异有统计学意义(P<0.05)。结论:临床治疗COPD急性加重期可考虑采用布地奈德福莫特罗粉吸入剂联合氨溴索的方式,可更好地改善患者肺功能、免疫功能,疗效更理想。Objective:Toanalyze the clinical effect of Budesonide and formoterol powder for inhalation combined with ambroxolof COPD exacerbations in the emergency.Methods:A retrospective analysis was conducted on 80 patients with COPD exacerbations admitted to our hospital from March 2019 to February 2020.They were divided into two groups according to treatment methods,among which 40 patients received Budesonide and Formoterol powder for inhalation(control group)andtheother 40 patients received Budesonide and Formoterol Powder for inhalation combined with am⁃broxol(observation group).The therapeutic effects,such as curative effect,lung function and immune function indicator⁃swere compared.Results:The therapeutic effect of observation group was significantly higher than that of control group(95%vs 72.50%,P<0.05).There was no significant difference in lung function between groups before treatment(P>0.05).After treatment,PEF,FEV1 and FVC in the observation group were higher than those in the control group(P<0.05).There was no statistical significanceinindexes of immune function before treatment(P>0.05).After treatment,CD4+/CD8+,CD4+and CD3+in the observation group were higher than those in the control group,with statistical sig⁃nificance(P<0.05).Conclusion:In the clinical treatment of COPD exacerbations,Budesonide and Formoterol Powder for inhalation combined with ambroxol can be considered,which can improve the lung function and immune function of patients,and the efficacy is more ideal.

关 键 词：COPD急性加重期 氨溴索 布地奈德福莫特罗吸入剂 肺功能 免疫功能 

分 类 号：R563.9[医药卫生—呼吸系统]